

# Claire L Vale

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/75201/publications.pdf>

Version: 2024-02-01

40  
papers

2,835  
citations

304743

22  
h-index

345221

36  
g-index

42  
all docs

42  
docs citations

42  
times ranked

4835  
citing authors

#	ARTICLE	IF	CITATIONS
1	Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials. <i>European Urology</i> , 2022, 81, 50-61.	1.9	43
2	A framework for prospective, adaptive meta-analysis (FAME) of aggregate data from randomised trials. <i>PLoS Medicine</i> , 2021, 18, e1003629.	8.4	21
3	Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data. <i>Lancet</i> , The, 2020, 396, 1422-1431.	13.7	224
4	Cytoreductive surgery (CRS) with hyperthermic intraoperative peritoneal chemotherapy (HIPEC) versus standard of care (SoC) in people with peritoneal metastases from colorectal, ovarian or gastric origin: protocol for a systematic review and individual participant data (IPD) meta-analyses of effectiveness and cost-effectiveness. <i>BMJ Open</i> , 2020, 10, e039314.	1.9	6
5	“PROUD to have been involved” an evaluation of participant and community involvement in the PROUD HIV prevention trial. <i>Research Involvement and Engagement</i> , 2020, 6, 13.	2.9	5
6	Adaptive platform trials using multi-arm, multi-stage protocols: getting fast answers in pandemic settings. <i>F1000Research</i> , 2020, 9, 1109.	1.6	8
7	Effectiveness and acceptability of methods of communicating the results of clinical research to lay and professional audiences: protocol for a systematic review. <i>Systematic Reviews</i> , 2019, 8, 150.	5.3	3
8	Reply to Comments on “Increased risk of second cancers at sites associated with HPV after a prior HPV-associated malignancy, a systematic review and meta-analysis” <i>British Journal of Cancer</i> , 2019, 120, 956-956.	6.4	0
9	Evidence Synthesis to Accelerate and Improve the Evaluation of Therapies for Metastatic Hormone-sensitive Prostate Cancer. <i>European Urology Focus</i> , 2019, 5, 137-143.	3.1	6
10	Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis. <i>European Urology</i> , 2019, 76, 115-124.	1.9	203
11	Increased risk of second cancers at sites associated with HPV after a prior HPV-associated malignancy, a systematic review and meta-analysis. <i>British Journal of Cancer</i> , 2019, 120, 256-268.	6.4	52
12	What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis. <i>Annals of Oncology</i> , 2018, 29, 1249-1257.	1.2	62
13	When participants get involved: reconsidering patient and public involvement in clinical trials at the MRC Clinical Trials Unit at UCL. <i>Trials</i> , 2018, 19, 95.	1.6	8
14	Response to letter commenting on published paper: Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2018, 94, 218-219.	2.8	0
15	Re: Christopher J.D. Wallis, Zachary Klaassen, Bimal Bhindi, et al. Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis. <i>Eur Urol</i> . In press. <a href="https://doi.org/10.1016/j.eururo.2017.10.002">https://doi.org/10.1016/j.eururo.2017.10.002</a> . <i>European Urology</i> , 2018, 73, e49-e50.	1.9	2
16	Priorities for methodological research on patient and public involvement in clinical trials: A modified Delphi process. <i>Health Expectations</i> , 2017, 20, 1401-1410.	2.6	36
17	Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2017, 84, 88-101.	2.8	128
18	Models and impact of patient and public involvement in studies carried out by the Medical Research Council Clinical Trials Unit at University College London: findings from ten case studies. <i>Trials</i> , 2016, 17, 376.	1.6	51

#	ARTICLE	IF	CITATIONS
19	Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. <i>Lancet Oncology</i> , The, 2016, 17, 243-256.	10.7	361
20	Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer. <i>The Cochrane Library</i> , 2015, 2015, CD007406.	2.8	123
21	Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma. <i>The Cochrane Library</i> , 2015, 2015, CD003915.	2.8	68
22	How individual participant data meta-analyses have influenced trial design, conduct, and analysis. <i>Journal of Clinical Epidemiology</i> , 2015, 68, 1325-1335.	5.0	60
23	Uptake of systematic reviews and meta-analyses based on individual participant data in clinical practice guidelines: descriptive study. <i>BMJ</i> , The, 2015, 350, h1088-h1088.	6.0	51
24	Should Tyrosine Kinase Inhibitors Be Considered for Advanced Non-Small-Cell Lung Cancer Patients With Wild Type EGFR? Two Systematic Reviews and Meta-Analyses of Randomized Trials. <i>Clinical Lung Cancer</i> , 2015, 16, 173-182.e4.	2.6	20
25	Individual Participant Data (IPD) Meta-analyses of Randomised Controlled Trials: Guidance on Their Use. <i>PLoS Medicine</i> , 2015, 12, e1001855.	8.4	245
26	Measuring the impact of methodological research: a framework and methods to identify evidence of impact. <i>Trials</i> , 2014, 15, 464.	1.6	16
27	Can trial quality be reliably assessed from published reports of cancer trials: evaluation of risk of bias assessments in systematic reviews. <i>BMJ</i> , The, 2013, 346, f1798-f1798.	6.0	43
28	Re: Andrew J. Stephenson, Michel Bolla, Alberto Briganti, et al. Postoperative Radiation Therapy for Pathologically Advanced Prostate Cancer After Radical Prostatectomy. <i>Eur Urol</i> 2012;61:443-51. <i>European Urology</i> , 2012, 62, e99.	1.9	4
29	Evaluation of patient involvement in a systematic review and meta-analysis of individual patient data in cervical cancer treatment. <i>Systematic Reviews</i> , 2012, 1, 23.	5.3	21
30	Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2012, 38, 618-625.	7.7	101
31	Involvement of consumers in studies run by the Medical Research Council Clinical Trials Unit: Results of a survey. <i>Trials</i> , 2012, 13, 9.	1.6	49
32	Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer. , 2010, , CD007406.		66
33	Re: Emilio Bria, Enzo Maria Ruggeri, Edmondo Terzoli, Francesco Cognetti, Camillo Francesco Pollera and Diana Giannarelli. Adjuvant Chemotherapy for Bladder Cancer: The Chance for Meta-analyses Comparison. <i>Eur Urol</i> 2007;51:576-7. <i>European Urology</i> , 2007, 51, 577-578.	1.9	0
34	Adjuvant chemotherapy for invasive bladder cancer (individual patient data). <i>The Cochrane Library</i> , 2006, , CD006018.	2.8	34
35	Concomitant chemoradiotherapy for cervical cancer: A systematic review and meta-analysis of individual patient data. <i>Gynecologic Oncology</i> , 2006, 100, 442-443.	1.4	12
36	Adjuvant Chemotherapy in Invasive Bladder Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data. <i>European Urology</i> , 2005, 48, 189-201.	1.9	410

#	ARTICLE	IF	CITATIONS
37	Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix. The Cochrane Library, 2005, , CD002225.	2.8	223
38	Compulsory registration of clinical trials: Publicly funded national register of trials would be best in the United Kingdom. BMJ: British Medical Journal, 2004, 329, 1043.3-1044.	2.3	3
39	Effects of adjusting for censoring on meta-analyses of time-to-event outcomes. International Journal of Epidemiology, 2002, 31, 107-111.	1.9	35
40	Adaptive platform trials using multi-arm, multi-stage protocols: getting fast answers in pandemic settings. F1000Research, 0, 9, 1109.	1.6	7